CNN reported late this morning that Johnson & Johnson COVID-19 vaccine is associated with “blood clot concerns.” This is “over six reported US cases of a ‘rare and severe’ type of blood clot.

All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination, according to a joint statement on Tuesday from Dr Anne Schuchat, principal deputy director of the CDC and Dr Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

‘CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance,’ the statement said.

‘FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution ….’

Johnson & Johnson issued a statement on Tuesday noting that the company has decided to ‘proactively delay the rollout’ of its vaccine in Europe.

Read complete coverage titled “CDC and FDA recommend US pause use of Johnson & Johnson’s Covid-19 vaccine over blood clot concerns” by Elizabeth Cohen and Jacqueline Howard, updated 10:09am today on CNN website.